Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26540039
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+Mol+Sci
2015 ; 16
(11
): 26077-86
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Application of CRISPR/Cas9 Technology to HBV
#MMPMID26540039
Lin G
; Zhang K
; Li J
Int J Mol Sci
2015[Nov]; 16
(11
): 26077-86
PMID26540039
show ga
More than 240 million people around the world are chronically infected with
hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two
families of drugs to treat HBV currently. However, none of these anti-virals
directly target the stable nuclear covalently closed circular DNA (cccDNA), which
acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and
secures virus persistence. Thus, the fact that only a small number of patients
treated achieve sustained viral response (SVR) or cure, highlights the need for
new therapies against HBV. The clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved
regions of the HBV genome. This results in robust viral suppression and provides
a promising tool for eradicating the virus. In this review, we discuss the
function and application of the CRISPR/Cas9 system as a novel therapy for HBV.
free
free
free
